Wet Age-related Macular Degeneration – Epidemiology – Epidemiology – Wet Age-Related Macular Degeneration – Mature Markets
Clarivate Epidemiology’s coverage of wet age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of wet age-related macular degeneration for each country, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s wet age-related macular degeneration forecast will answer the following questions:
- Of all people diagnosed with wet age-related macular degeneration, how many in each country in the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of wet age-related macular degeneration over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 6 wet age-related macular degeneration patient populations, as follows:
- Total prevalent cases of wet AMD
- Total prevalent cases of mixed AMD
- Diagnosed prevalent cases of wet AMD
- Undiagnosed prevalent cases of wet AMD
- Diagnosed drug-treated cases of wet AMD
- Diagnosed non-drug-treated cases of wet AMD
Note: Coverage may vary by country.
